NCT07735091Not yet recruiting
A Blood Pressure-Lowering Diet for Preventing and Managing Hypertension
Translation of a Blood Pressure-Lowering Dietary Pattern for Hypertension Prevention and Control: A Cluster-Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This cluster-randomized controlled trial will evaluate whether a 3-month culturally adapted blood pressure-lowering dietary, called the Eastern Blood Pressure-Lowering Diet, can improve blood pressure and related health outcomes in Chinese adults with primary hypertension. Approximately 800 participants from 16 workplace-based clusters will be assigned to either a standard hypertension management group or a dietary intervention group. Both groups will receive usual hypertension care, including health education and medication treatment when clinically indicated. In addition, participants in the dietary intervention group will receive specially designed weekday lunches, low-sodium salt and reduced-sodium seasonings, and app-based support for dietary recording and adherence monitoring. The main outcome is change in resting systolic and diastolic blood pressure. Other outcomes include body weight, waist circumference, body fat, blood glucose, blood lipids, homocysteine, kidney function, estimated 24-hour urinary sodium and potassium excretion, lifestyle behaviors, sleep, psychological well-being, and the occurrence of hypertension-related complications or cardiovascular and cerebrovascular events. Blood, urine, and stool samples will also be analyzed to explore possible metabolic and gut microbiome mechanisms underlying the effects of the dietary intervention. The active dietary intervention will last 3 months, and participants will be followed for up to 24 months.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- First submitted
- 18 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Peking University
- Diseases
- High blood pressure
- NCT number
- NCT07735091
What you commit to
- Study type: Interventional
- Planned participants: 800
- From 1 Aug 2026 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major cardiovascular or cerebrovascular event within the previous 6 months, such as myocardial infarction or stroke.
Other illness
- Secondary hypertension.
- Serious food allergy or intolerance to major foods included in the intervention diet, such as nuts, dairy products, or gluten-containing foods.
- Severe cardiopulmonary disease, such as heart failure or severe asthma.
- Cancer, advanced kidney disease, severe liver disease, or another serious medical condition.
- A medical condition requiring a specialized therapeutic diet that would interfere with the study intervention.
- Severe psychiatric illness.
- Severe cognitive impairment that prevents understanding of the informed consent form or compliance with study procedures.
- Hearing impairment or physical disability that would substantially interfere with participation.
- Any other condition that, in the judgment of the research team, makes the individual unsuitable for participation.
Other
- Pregnancy, breastfeeding, or planning to become pregnant during the study period.
Who the study is looking for
- Aged 18 to 60 years.
- Employed by Shengli Oilfield and regularly receiving meals from a participating workplace canteen.
- Regularly eats at the participating canteen, generally on at least 4 working days per week.
- Diagnosed with primary hypertension by a qualified medical institution, or meets the diagnostic criterion of systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg on 3 measurements obtained on different days.
- Hypertension is clinically stable.
- Antihypertensive medication regimen is stable, when applicable.
- Able and willing to comply with the dietary intervention, study assessments, and follow-up procedures.
- Provides written informed consent voluntarily.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sinopec Shengli Petroleum Administrative Bureau Co., Ltd. Coordinator of this site? Confirm its status | Dongying | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.